Purespring Therapeutics

We are Purespring. We are on a mission to radically transform the treatment of kidney diseases.

Add To Watchlist
General Information
Company Name
Purespring Therapeutics
Founded Year
2020
Location (Offices)
London, United Kingdom +1
Founders / Decision Makers
Pille Harrison - VP Clinical Development Julian Hanak - Chief Development Officer Moin Saleem - Co-founder and Chief Scientific Officer Ronny Renfurm - Chief Medical Officer
Number of Employees
55
Industries
Biotechnology, Health and Wellness
Funding Stage
Series B
Social Media

Purespring Therapeutics - Company Profile

Purespring Therapeutics is a biotechnology startup founded in 2020 and based in the United Kingdom. Backed by £45 million in funding from Syncona Ltd, Purespring is focused on revolutionizing the treatment of kidney diseases. The company's pioneering approach involves targeting the podocyte, a specialized kidney cell, through AAV gene therapy, based on the groundbreaking work of Professor Moin Saleem at the University of Bristol. In the latest development, Purespring secured an impressive £80.00M in Series B investment on 09 October 2024. The investors in this round include Sofinnova Partners, Forbion, Gilde Healthcare, British Patient Capital, and Syncona Investment Management. Purespring's steadfast commitment to advancing kidney disease treatment makes it a compelling prospect for potential venture capital investment.

Taxonomy: gene therapy, kidney diseases, AAV gene therapy, podocytes, specialized kidney cells, medical research, precision medicine, therapeutics, genetic medicine, biomedical innovation

Funding Rounds & Investors of Purespring Therapeutics (2)

View All
Funding Stage Amount No. Investors Investors Date
Series B £80.00M 5
Sofinnova Partners, investor in Purespring Therapeutics's Series B round Forbion, investor in Purespring Therapeutics's Series B round Gilde Healthcare, investor in Purespring Therapeutics's Series B round British Patient Capital, investor in Purespring Therapeutics's Series B round Syncona Investment Management, investor in Purespring Therapeutics's Series B round
09 Oct 2024
Series A £45.00M 1
Syncona Investment Management, investor in Purespring Therapeutics's Series A round
19 Nov 2020

Latest News of Purespring Therapeutics

View All

No recent news or press coverage available for Purespring Therapeutics.

Similar Companies to Purespring Therapeutics

View All
Nephrogen - Similar company to Purespring Therapeutics
Nephrogen Curative gene therapies for kidney diseases
Rejuvenate Bio - Similar company to Purespring Therapeutics
Rejuvenate Bio Targeting the core drivers of chronic age-related diseases to reverse pre-existing conditions in humans
Rila Therapeutics - Similar company to Purespring Therapeutics
Rila Therapeutics Addressing the burden of chronic fibrotic disease
Clinical Renal Associates - Similar company to Purespring Therapeutics
Clinical Renal Associates Dedicated Kidney Specialist- Serving Southeast Pennsylvania for over 40 Years.
Gallant Therapeutics - Similar company to Purespring Therapeutics
Gallant Therapeutics Setting a New Standard in Animal Health🐾 Harnessing the Power of Stem Cell Therapy to Treat the Root Cause of Diseases
Circle Decoration Circle Decoration

Want to dive deeper into Purespring Therapeutics? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now